EUVIMEDEUVIMED entdecken
Fallbericht

Pure Red Cell Aplasia Associated With Recipient B‐Cell Mixed Chimerism Successfully Treated With Rituximab

Norifumi Yokoyama iD, Taichi Miyazaki iD, Tomoaki Hirate, Ikko Ohshiro iD, Mari Mori, Kaori Kanda, Kunihiro Shinoda iD

Pediatric Transplantation · 2026

DOI: 10.1111/petr.70352 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Pediatric Transplantation, 2026. Verfasst von Norifumi Yokoyama und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics・Pediatric Hematology/Oncology, Gifu Municipal Hospital, Gifu, Japan. Hauptthemen laut MEDLINE: B-Lymphocytes, Hematopoietic Stem Cell Transplantation, Immunologic Factors, Red-Cell Aplasia, Pure. Die Arbeit nennt 10 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Pure red cell aplasia (PRCA) is a rare but clinically significant complication of allogeneic hematopoietic stem cell transplantation (HSCT), particularly in patients with major ABO incompatibility. Although mixed chimerism is usually evaluated using whole‐blood or T‐cell–based assays, these approaches may fail to detect lineage‐specific immune dysregulation relevant to posttransplant immune complications.

Methods

We report a pediatric case of late‐onset PRCA after reduced‐intensity allogeneic HSCT. Clinical course and lineage‐specific chimerism analyses were retrospectively reviewed.

Results

Lineage‐specific chimerism analysis demonstrated persistent recipient B‐cell mixed chimerism, whereas T‐cell and granulocyte fractions showed complete donor chimerism. Given the suspected pathogenic role of residual recipient B cells, rituximab was administered as a targeted B‐cell–directed therapy. This resulted in reticulocyte recovery, resolution of transfusion dependence, and conversion to complete donor B‐cell chimerism.

Conclusion

This case suggests that recipient B‐cell persistence may contribute to the pathogenesis of posttransplant PRCA and highlights the potential value of lineage‐specific chimerism analysis in clarifying the underlying mechanism and guiding mechanism‐based therapy, including rituximab.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

B-LymphocytesHematopoietic Stem Cell TransplantationImmunologic FactorsRed-Cell Aplasia, PureRituximabTransplantation ChimeraHumansChimerismTransplantation, HomologousTreatment Outcome

Stichwörter der Autor:innen

hematopoietic stem cell transplantationmixed chimerismpure red cell aplasiarituximab

Substanzen

Immunologic FactorsRituximab

Autor:innen und Institutionen

  • Department of Pediatrics・Pediatric Hematology/Oncology, Gifu Municipal Hospital, Gifu, Japan.

ORCID-Profile: Norifumi Yokoyama, Taichi Miyazaki, Ikko Ohshiro, Kunihiro Shinoda

Zitieren

APA

Yokoyama, N., Miyazaki, T., Hirate, T., Ohshiro, I., Mori, M., Kanda, K., & Shinoda, K. (2026). Pure Red Cell Aplasia Associated With Recipient B‐Cell Mixed Chimerism Successfully Treated With Rituximab. Pediatric Transplantation. https://doi.org/10.1111/petr.70352

Vancouver

Yokoyama N, Miyazaki T, Hirate T, Ohshiro I, Mori M, Kanda K, et al. Pure Red Cell Aplasia Associated With Recipient B‐Cell Mixed Chimerism Successfully Treated With Rituximab. Pediatric Transplantation. 2026. doi:10.1111/petr.70352

BibTeX
@article{Yokoyama2026,
  author = {Yokoyama, Norifumi and Miyazaki, Taichi and Hirate, Tomoaki and Ohshiro, Ikko and Mori, Mari and Kanda, Kaori and Shinoda, Kunihiro},
  title = {Pure Red Cell Aplasia Associated With Recipient B‐Cell Mixed Chimerism Successfully Treated With Rituximab},
  journal = {Pediatric Transplantation},
  year = {2026},
  doi = {10.1111/petr.70352}
}
Kostenlos starten →